Functional characterization of Filamin A interacting protein 1-like, a novel candidate for antivascular cancer therapy

Mijung Kwon, Engy Hanna, Dominique Lorang, Mei He, John S. Quick, Asha Adem, Christina Stevenson, Joon Yong Chung, Stephen M. Hewitt, Enrique Zudaire, Dominic Esposito, Frank Cuttitta, Steven K. Libutti

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Inhibiting angiogenesis has become a major therapeutic strategy for cancer treatment. To identify common intracellular mediators, we previously analyzed gene expression profiles of endothelial cells after treatment with angiogenesis inhibitors. Filamin A interacting protein 1-like (FILIP1L; previously known as down-regulated in ovarian cancer 1) was identified as one of the genes up-regulated in endothelial cells in response to these inhibitors. However, the expression and function of FILIP1L protein is uncharacterized. Here, we provide the first description of the expression and specific subcellular localization of FILIP1L protein in human tissue. Overexpression of FILIP1L resulted in inhibition of cell proliferation and migration and increased apoptosis. In addition, overexpression of FILIP1L truncation mutants showed differential antiproliferative activity. A COOH terminal truncation mutant (FILIP1LΔC103) was more potent than wild-type FILIP1L in mediating this activity. Targeted expression of FILIP1LΔC103 in tumor vasculature inhibited tumor growth in vivo. Overall, these findings suggest that the novel protein FILIP1L may be an important mediator of the effects of angiogenesis inhibitors and that FILIP1L has the potential to be an antivascular reagent for cancer therapy.

Original languageEnglish (US)
Pages (from-to)7332-7341
Number of pages10
JournalCancer Research
Volume68
Issue number18
DOIs
StatePublished - Sep 15 2008
Externally publishedYes

Fingerprint

Filamins
Angiogenesis Inhibitors
Neoplasms
Proteins
Endothelial Cells
Therapeutics
Transcriptome
Ovarian Neoplasms
Cell Movement
Cell Proliferation
Apoptosis
Growth
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Functional characterization of Filamin A interacting protein 1-like, a novel candidate for antivascular cancer therapy. / Kwon, Mijung; Hanna, Engy; Lorang, Dominique; He, Mei; Quick, John S.; Adem, Asha; Stevenson, Christina; Chung, Joon Yong; Hewitt, Stephen M.; Zudaire, Enrique; Esposito, Dominic; Cuttitta, Frank; Libutti, Steven K.

In: Cancer Research, Vol. 68, No. 18, 15.09.2008, p. 7332-7341.

Research output: Contribution to journalArticle

Kwon, M, Hanna, E, Lorang, D, He, M, Quick, JS, Adem, A, Stevenson, C, Chung, JY, Hewitt, SM, Zudaire, E, Esposito, D, Cuttitta, F & Libutti, SK 2008, 'Functional characterization of Filamin A interacting protein 1-like, a novel candidate for antivascular cancer therapy', Cancer Research, vol. 68, no. 18, pp. 7332-7341. https://doi.org/10.1158/0008-5472.CAN-08-1087
Kwon, Mijung ; Hanna, Engy ; Lorang, Dominique ; He, Mei ; Quick, John S. ; Adem, Asha ; Stevenson, Christina ; Chung, Joon Yong ; Hewitt, Stephen M. ; Zudaire, Enrique ; Esposito, Dominic ; Cuttitta, Frank ; Libutti, Steven K. / Functional characterization of Filamin A interacting protein 1-like, a novel candidate for antivascular cancer therapy. In: Cancer Research. 2008 ; Vol. 68, No. 18. pp. 7332-7341.
@article{133043f1eedf4bc690db3ada401a2953,
title = "Functional characterization of Filamin A interacting protein 1-like, a novel candidate for antivascular cancer therapy",
abstract = "Inhibiting angiogenesis has become a major therapeutic strategy for cancer treatment. To identify common intracellular mediators, we previously analyzed gene expression profiles of endothelial cells after treatment with angiogenesis inhibitors. Filamin A interacting protein 1-like (FILIP1L; previously known as down-regulated in ovarian cancer 1) was identified as one of the genes up-regulated in endothelial cells in response to these inhibitors. However, the expression and function of FILIP1L protein is uncharacterized. Here, we provide the first description of the expression and specific subcellular localization of FILIP1L protein in human tissue. Overexpression of FILIP1L resulted in inhibition of cell proliferation and migration and increased apoptosis. In addition, overexpression of FILIP1L truncation mutants showed differential antiproliferative activity. A COOH terminal truncation mutant (FILIP1LΔC103) was more potent than wild-type FILIP1L in mediating this activity. Targeted expression of FILIP1LΔC103 in tumor vasculature inhibited tumor growth in vivo. Overall, these findings suggest that the novel protein FILIP1L may be an important mediator of the effects of angiogenesis inhibitors and that FILIP1L has the potential to be an antivascular reagent for cancer therapy.",
author = "Mijung Kwon and Engy Hanna and Dominique Lorang and Mei He and Quick, {John S.} and Asha Adem and Christina Stevenson and Chung, {Joon Yong} and Hewitt, {Stephen M.} and Enrique Zudaire and Dominic Esposito and Frank Cuttitta and Libutti, {Steven K.}",
year = "2008",
month = "9",
day = "15",
doi = "10.1158/0008-5472.CAN-08-1087",
language = "English (US)",
volume = "68",
pages = "7332--7341",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - Functional characterization of Filamin A interacting protein 1-like, a novel candidate for antivascular cancer therapy

AU - Kwon, Mijung

AU - Hanna, Engy

AU - Lorang, Dominique

AU - He, Mei

AU - Quick, John S.

AU - Adem, Asha

AU - Stevenson, Christina

AU - Chung, Joon Yong

AU - Hewitt, Stephen M.

AU - Zudaire, Enrique

AU - Esposito, Dominic

AU - Cuttitta, Frank

AU - Libutti, Steven K.

PY - 2008/9/15

Y1 - 2008/9/15

N2 - Inhibiting angiogenesis has become a major therapeutic strategy for cancer treatment. To identify common intracellular mediators, we previously analyzed gene expression profiles of endothelial cells after treatment with angiogenesis inhibitors. Filamin A interacting protein 1-like (FILIP1L; previously known as down-regulated in ovarian cancer 1) was identified as one of the genes up-regulated in endothelial cells in response to these inhibitors. However, the expression and function of FILIP1L protein is uncharacterized. Here, we provide the first description of the expression and specific subcellular localization of FILIP1L protein in human tissue. Overexpression of FILIP1L resulted in inhibition of cell proliferation and migration and increased apoptosis. In addition, overexpression of FILIP1L truncation mutants showed differential antiproliferative activity. A COOH terminal truncation mutant (FILIP1LΔC103) was more potent than wild-type FILIP1L in mediating this activity. Targeted expression of FILIP1LΔC103 in tumor vasculature inhibited tumor growth in vivo. Overall, these findings suggest that the novel protein FILIP1L may be an important mediator of the effects of angiogenesis inhibitors and that FILIP1L has the potential to be an antivascular reagent for cancer therapy.

AB - Inhibiting angiogenesis has become a major therapeutic strategy for cancer treatment. To identify common intracellular mediators, we previously analyzed gene expression profiles of endothelial cells after treatment with angiogenesis inhibitors. Filamin A interacting protein 1-like (FILIP1L; previously known as down-regulated in ovarian cancer 1) was identified as one of the genes up-regulated in endothelial cells in response to these inhibitors. However, the expression and function of FILIP1L protein is uncharacterized. Here, we provide the first description of the expression and specific subcellular localization of FILIP1L protein in human tissue. Overexpression of FILIP1L resulted in inhibition of cell proliferation and migration and increased apoptosis. In addition, overexpression of FILIP1L truncation mutants showed differential antiproliferative activity. A COOH terminal truncation mutant (FILIP1LΔC103) was more potent than wild-type FILIP1L in mediating this activity. Targeted expression of FILIP1LΔC103 in tumor vasculature inhibited tumor growth in vivo. Overall, these findings suggest that the novel protein FILIP1L may be an important mediator of the effects of angiogenesis inhibitors and that FILIP1L has the potential to be an antivascular reagent for cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=54749103499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54749103499&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-08-1087

DO - 10.1158/0008-5472.CAN-08-1087

M3 - Article

C2 - 18794120

AN - SCOPUS:54749103499

VL - 68

SP - 7332

EP - 7341

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 18

ER -